About the Company

Celyad (NasdaqGM: CYAD) is a biotherapeutics company developing cell therapies for the treatment of cardiovascular disease and cancer. The Company’s Cardiopoiesis platform creates autologous cardiac progenitor cell therapies for heart failure. Celyad’s lead product candidate C-Cure is currently in a Phase III trial in Europe, with a full data readout expected in the second half of 2016. The Company’s recently in-licensed chimeric antigen receptor T cell (CAR-T) platform utilizes chimeric natural killer (NK-cell) receptors to recognize and eliminate tumor cells. CAR-NKG2D is Celyad’s lead oncology product candidate that is currently in a Phase I trial for acute myeloid leukemia (AML) and mutltiple myeloma (MM). Data from the trial are expected in the second half of 2016.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research